Compare GCBC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | BWAY |
|---|---|---|
| Founded | 1889 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.8M | 450.8M |
| IPO Year | 1998 | N/A |
| Metric | GCBC | BWAY |
|---|---|---|
| Price | $22.18 | $13.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 7.0K | ★ 118.8K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | ★ 26.21 | N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $4,117,000.00 | N/A |
| Revenue This Year | N/A | $301.23 |
| Revenue Next Year | N/A | $24.33 |
| P/E Ratio | ★ $19.49 | $81.98 |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $20.00 | $7.84 |
| 52 Week High | $26.04 | $26.63 |
| Indicator | GCBC | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 29.80 |
| Support Level | $21.39 | $11.55 |
| Resistance Level | $23.34 | $17.20 |
| Average True Range (ATR) | 0.58 | 1.07 |
| MACD | -0.08 | -0.81 |
| Stochastic Oscillator | 22.29 | 15.32 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.